4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 113 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 2.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $82,331,449 | -34.1% | 3,922,413 | 0.0% | 2.31% | -32.9% |
| Q1 2024 | $124,968,078 | +53.9% | 3,922,413 | -2.1% | 3.44% | +69.1% |
| Q4 2023 | $81,190,187 | +59.2% | 4,007,413 | 0.0% | 2.03% | +47.7% |
| Q3 2023 | $51,014,367 | -29.6% | 4,007,413 | 0.0% | 1.38% | -31.8% |
| Q2 2023 | $72,413,953 | +5.1% | 4,007,413 | 0.0% | 2.02% | -19.9% |
| Q1 2023 | $68,887,429 | -22.6% | 4,007,413 | 0.0% | 2.52% | -33.0% |
| Q4 2022 | $89,004,643 | +176.2% | 4,007,413 | 0.0% | 3.76% | +182.2% |
| Q3 2022 | $32,220,000 | +15.2% | 4,007,413 | 0.0% | 1.33% | -1.5% |
| Q2 2022 | $27,972,000 | -30.6% | 4,007,413 | +50.4% | 1.35% | -16.2% |
| Q1 2022 | $40,288,000 | -8.5% | 2,664,521 | +32.8% | 1.61% | +0.9% |
| Q4 2021 | $44,009,000 | -18.6% | 2,005,862 | 0.0% | 1.60% | -24.3% |
| Q3 2021 | $54,098,000 | +12.0% | 2,005,862 | 0.0% | 2.11% | +16.6% |
| Q2 2021 | $48,301,000 | +8.0% | 2,005,862 | +94.5% | 1.81% | +7.9% |
| Q1 2021 | $44,728,000 | -2.4% | 1,031,070 | -6.8% | 1.68% | -7.0% |
| Q4 2020 | $45,847,000 | – | 1,106,070 | – | 1.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |